Abstract: A method for adjusting a chromaticity of a liquid crystal display (LCD) is provided. Firstly, a light-on-test is performed to a plurality of backlight modules according to a standard gamma curve of a liquid crystal panel to obtain a color space of a plurality of LCDs formed by the backlight modules and the liquid crystal panel. The color space has a plurality of chromaticity coordinate values for representing chromaticities of the LCDs. The standard gamma curve is a relation curve of brightness corresponding to different gamma voltages inputted to the liquid crystal panel. Next, the color space is divided into a predetermined chromaticity area and a plurality of adjusting chromaticity areas according to a standard chromaticity range. Finally, a plurality of gamma voltage adjusting values corresponding to the adjusting chromaticity areas is obtained according to the relative position relationship between the adjusting chromaticity areas and the predetermined chromaticity area.

Abstract: A syringe includes a hollow barrel, a hollow plunger movable within the barrel and a needle assembly secured within and at a distal end of the barrel. The needle assembly includes a needle holder, a resilient member that biases the needle holder toward the proximal end opening of the barrel, and a retaining member releasably secured to the needle holder via a reduced material section. The retaining member maintains the needle holder at the distal end of the barrel against the bias of the resilient member. When the plunger is fully depressed within the barrel, the plunger engages the needle holder such that the retaining member is forced to break away and separate from the needle holder along the reduced material section to facilitate retraction of the needle holder and a needle secured to the needle holder into the retraction cavity disposed within the plunger.

Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.

Abstract: A syringe includes a hollow barrel, a hollow plunger movable within the barrel and a needle assembly secured within and at a distal end of the barrel. The needle assembly includes a needle holder, a resilient member that biases the needle holder toward the proximal end opening of the barrel, and a retaining member releasably secured to the needle holder via a reduced material section. The retaining member maintains the needle holder at the distal end of the barrel against the bias of the resilient member. When the plunger is fully depressed within the barrel, the plunger engages the needle holder such that the retaining member is forced to break away and separate from the needle holder along the reduced material section to facilitate retraction of the needle holder and a needle secured to the needle holder into the retraction cavity disposed within the plunger.

Abstract: A frame assembly for a double-seat baby stroller is provided. The frame assembly comprises: a first frame including a first main post, plural first bars, plural second bars, plural third bar, a central post and a first folding device pivotally connected to one another; and a second frame including a second main post, plural fourth bars, plural fifth bars, plural sixth bar, the central post and a second folding device pivotally connected to one another. The frame assembly is characterized by further comprising a linking mechanism connecting one of the bars of the first frame and one of the bars of the second frame, wherein when the second main post of the second frame and the central post become close to each other, the one of the bars of the first frame is driven to move via the linking mechanism by the one of the bars of the second frame, so that the first main post of the first frame and the central post become close to each other.

Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.

Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.

Abstract: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.

Abstract: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.

Abstract: A frame assembly for a double-seat baby stroller is provided. The frame assembly comprises: a first frame including a first main post, plural first bars, plural second bars, plural third bar, a central post and a first folding device pivotally connected to one another; and a second frame including a second main post, plural fourth bars, plural fifth bars, plural sixth bar, the central post and a second folding device pivotally connected to one another. The frame assembly is characterized by further comprising a linking mechanism connecting one of the bars of the first frame and one of the bars of the second frame, wherein when the second main post of the second frame and the central post become close to each other, the one of the bars of the first frame is driven to move via the linking mechanism by the one of the bars of the second frame, so that the first main post of the first frame and the central post become close to each other.

Abstract: The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.

Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.

Abstract: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.

Abstract: The present invention is directed to novel polypeptides belonging to the fibroblast growth factor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating obesity are provided.

Abstract: The present invention is directed to novel polypeptides belonging to the fibroblast growth factor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating obesity are provided.

Abstract: An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence SEQ ID NO:1, polynucleotides encoding these peptides, and antibodies to the polypeptides are useful in treating metabolic disorders or disorders associated with changes in adipose tissue physiological function or mass.

Abstract: The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.